NEW YORK, Dec. 14 /PRNewswire/ -- Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera(R), in the U.S. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court.
Exubera is the only inhalable form of insulin to be approved by the FDA. The court's decision allows the product to remain on the U.S. market, and available to patients, while the case proceeds to trial.
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888.Pfizer IncCONTACT: Bryant Haskins, +1-212-733-8719
Web site: http://www.pfizer.com/
